1. Home
  2. SGMT vs AIRG Comparison

SGMT vs AIRG Comparison

Compare SGMT & AIRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGMT
  • AIRG
  • Stock Information
  • Founded
  • SGMT 2006
  • AIRG 1995
  • Country
  • SGMT United States
  • AIRG United States
  • Employees
  • SGMT N/A
  • AIRG 122
  • Industry
  • SGMT
  • AIRG Radio And Television Broadcasting And Communications Equipment
  • Sector
  • SGMT
  • AIRG Technology
  • Exchange
  • SGMT Nasdaq
  • AIRG Nasdaq
  • Market Cap
  • SGMT 93.7M
  • AIRG 107.7M
  • IPO Year
  • SGMT 2023
  • AIRG 2016
  • Fundamental
  • Price
  • SGMT $5.18
  • AIRG $9.66
  • Analyst Decision
  • SGMT Strong Buy
  • AIRG Strong Buy
  • Analyst Count
  • SGMT 5
  • AIRG 2
  • Target Price
  • SGMT $21.60
  • AIRG $11.75
  • AVG Volume (30 Days)
  • SGMT 772.8K
  • AIRG 35.1K
  • Earning Date
  • SGMT 11-13-2024
  • AIRG 11-12-2024
  • Dividend Yield
  • SGMT N/A
  • AIRG N/A
  • EPS Growth
  • SGMT N/A
  • AIRG N/A
  • EPS
  • SGMT N/A
  • AIRG N/A
  • Revenue
  • SGMT $2,000,000.00
  • AIRG $55,586,000.00
  • Revenue This Year
  • SGMT N/A
  • AIRG $13.95
  • Revenue Next Year
  • SGMT N/A
  • AIRG $18.52
  • P/E Ratio
  • SGMT N/A
  • AIRG N/A
  • Revenue Growth
  • SGMT N/A
  • AIRG N/A
  • 52 Week Low
  • SGMT $2.25
  • AIRG $2.25
  • 52 Week High
  • SGMT $20.71
  • AIRG $10.34
  • Technical
  • Relative Strength Index (RSI)
  • SGMT 47.83
  • AIRG 54.95
  • Support Level
  • SGMT $5.61
  • AIRG $9.12
  • Resistance Level
  • SGMT $6.40
  • AIRG $10.34
  • Average True Range (ATR)
  • SGMT 0.52
  • AIRG 0.43
  • MACD
  • SGMT -0.10
  • AIRG -0.02
  • Stochastic Oscillator
  • SGMT 17.57
  • AIRG 49.33

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

About AIRG Airgain Inc.

Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.

Share on Social Networks: